痛风和新型降尿酸药:非布索坦

A new Urate-lowering drug-Febuxostat

非布索坦是一种新型非嘌呤类黄嘌呤氧化酶抑制药,对氧化型和还原型的黄嘌呤氧化酶均有抑制作用,其对黄嘌呤氧化酶的抑制具有特异性。与别嘌醇相比,非布索坦可快速降低血尿酸水平,尤其对于存在轻中度肾功能不全的患者无需调整剂量,且无明显不良反应。临床上,对于存在轻中度肾功能损害、别嘌醇不耐受、治疗不能使血尿酸降至目标值的患者应考虑选用非布索坦。在应用非布索坦的前6个月应合用秋水仙碱或非甾体消炎药以避免痛风的急性发作。

Febuxostat is a new non -purine xanthine oxidase inhibitor, concluding the oxidized and reduced xanthine oxidase,the inhibition of xanthine oxidase is specified. Compared with allopurinol, Febuxostat reduce serum urate quickly, especially for the patients with mild to moderate renal dysfunction, no dosage adjustment, and no significant adverse reactions. Clinically,for the patients with mild to moderate renal impairment, allopuri- nol intolerant, unable to maintain the serum urate in the target level, Febuxostat should be considered. Fe- buxostat should be combined with colchicine or non - steroidal anti - inflammatory drugs in the application of the first six months to prevent acute gout attacks.